# Evommune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/evommune

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.evommune.com
- Total disclosed funding: $260M
- Latest round: Series C (Oct 31, 2024)
- Investors on record: 19

## About

Evommune, Inc. is a US-based biotechnology company focused on developing innovative therapies to treat chronic inflammatory diseases, specifically targeting conditions like Chronic Spontaneous Urticaria and Atopic Dermatitis.Founded in 2020 and headquartered in Palo Alto, US, Evommune, Inc. specializes in biotech advancements for chronic inflammatory conditions. The company was established under the leadership of CEO Luis Peña, who has a history in the biotechnology sector. Evommune has successfully completed 5 funding rounds, with the most recent deal occurring on October 31, 2024, when it raised USD 115.00 mn during its Series C funding round, bringing the total amount raised to USD 115.00 mn and valuing the company at USD 293.46 mn.Evommune specializes in the development of innovative therapies aimed at treating chronic inflammatory diseases, with a primary focus on conditions such as Chronic Spontaneous Urticaria and Atopic Dermatitis. Their lead product, EVO756, is an MRGPRX2 antagonist currently undergoing Phase 2 clinical trials, targeting the underlying mechanisms of chronic inflammation. Additionally, Evommune is advancing EVO301, an IL-18 targeted fusion protein, also in Phase 2 trials, designed to meet the needs of adult patients suffering from Atopic Dermatitis. The therapeutic offerings aim to address unmet medical needs in regions including North America and Europe.Evommune's revenue model is primarily centered around clinical trials and partnerships with the pharmaceutical industry. The company engages in business-to-business transactions, collaborating with healthcare providers and research institutions for therapy development and commercialization. Revenue is generated through strategic partnerships that may involve co-development agreements and licensing deals for its flagship products, such as EVO756 and EVO301. The structure typically includes milestone payments contingent upon regulatory approvals and sales achievements. As the products are still in clinical trials, specific pricing plans have not been disclosed.In October 2024, Evommune, Inc. raised USD 115.00 mn in Series C funding co-led by new investors RA Capital Management and Sectoral Asset Management, with additional participation from various other investors. The company will utilize this funding to support the development of its leading clinical initiatives focused on atopic dermatitis and chronic urticaria. Evommune plans to introduce new products designed for these conditions and expand into new markets within North America and Europe by 2025.

## Funding rounds

- Series C, Oct 31, 2024, $115M — Andera Partners, EQT Life Sciences, Marshall Wace, Beiersdorf AG, Longwood Fund, Sectoral Asset Management, Verition Fund Management, RTW Investments, RA Capital Management, B Capital, Pivotal Life Sciences, Amplitude, FemHealth Ventures, Avego Bioscience Capital, ADAR1 Capital Management, SymBiosis Capital Management, Allostery Investments, NEXTBio Capital
- Series B, Apr 26, 2023, $50M — Andera Partners, EQT Life Sciences, Arix Bioscience, Pivotal Life Sciences, Amplitude, SymBiosis Capital Management
- Series A, Sep 9, 2021, $83M — Andera Partners, EQT Life Sciences, Pivotal Life Sciences
- Seed, Jun 22, 2020, $12M — Pivotal Life Sciences

## Investors

- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Seed, Series A, Series B, Series C
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series A, Series B, Series C
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A, Series B, Series C
- Arix Bioscience (https://capitalatlas.ai/funds/arix-bioscience) — Series B
- Amplitude (https://capitalatlas.ai/funds/amplitude) — Series B, Series C
- SymBiosis Capital Management (https://capitalatlas.ai/funds/symbiosis-capital-management) — Series B, Series C
- Marshall Wace (https://capitalatlas.ai/funds/marshall-wace) — Series C
- Beiersdorf AG — Series C
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series C
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series C
- Verition Fund Management — Series C
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- B Capital (https://capitalatlas.ai/funds/b-capital) — Series C
- FemHealth Ventures (https://capitalatlas.ai/funds/femhealth-ventures) — Series C
- Avego Bioscience Capital — Series C
- ADAR1 Capital Management (https://capitalatlas.ai/funds/adar1-capital-management) — Series C
- Allostery Investments — Series C
- NEXTBio Capital — Series C